Founded in 2021, LIVEOME Co., Ltd. is a South Korean biotechnology company specializing in the development of next-generation microbiome therapeutics aimed at treating incurable diseases. As a subsidiary of the biopharmaceutical company Medy-Tox Inc., LIVEOME focuses on creating disease-specific live biotherapeutic products (LBP) to address conditions such as Crohn's disease and ulcerative colitis.

Microbiome Therapeutics Development Platform: LIVEOME utilizes advanced microbiome research to develop LBPs tailored to specific diseases, aiming to restore healthy microbiota balance and improve patient outcomes.

Private

Biotech